scispace - formally typeset
Search or ask a question
Author

Ryan G. Lim

Bio: Ryan G. Lim is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Huntington's disease & Neurodegeneration. The author has an hindex of 9, co-authored 15 publications receiving 818 citations.

Papers
More filters
Journal ArticleDOI
Alexandra B Keenan1, Sherry L. Jenkins1, Kathleen M. Jagodnik1, Simon Koplev1, Edward He1, Denis Torre1, Zichen Wang1, Anders B. Dohlman1, Moshe C. Silverstein1, Alexander Lachmann1, Maxim V. Kuleshov1, Avi Ma'ayan1, Vasileios Stathias2, Raymond Terryn2, Daniel J. Cooper2, Michele Forlin2, Amar Koleti2, Dusica Vidovic2, Caty Chung2, Stephan C. Schürer2, Jouzas Vasiliauskas3, Marcin Pilarczyk3, Behrouz Shamsaei3, Mehdi Fazel3, Yan Ren3, Wen Niu3, Nicholas A. Clark3, Shana White3, Naim Al Mahi3, Lixia Zhang3, Michal Kouril3, John F. Reichard3, Siva Sivaganesan3, Mario Medvedovic3, Jaroslaw Meller3, Rick J. Koch1, Marc R. Birtwistle1, Ravi Iyengar1, Eric A. Sobie1, Evren U. Azeloglu1, Julia A. Kaye4, Jeannette Osterloh4, Kelly Haston4, Jaslin Kalra4, Steve Finkbiener4, Jonathan Z. Li5, Pamela Milani5, Miriam Adam5, Renan Escalante-Chong5, Karen Sachs5, Alexander LeNail5, Divya Ramamoorthy5, Ernest Fraenkel5, Gavin Daigle6, Uzma Hussain6, Alyssa Coye6, Jeffrey D. Rothstein6, Dhruv Sareen7, Loren Ornelas7, Maria G. Banuelos7, Berhan Mandefro7, Ritchie Ho7, Clive N. Svendsen7, Ryan G. Lim8, Jennifer Stocksdale8, Malcolm Casale8, Terri G. Thompson8, Jie Wu8, Leslie M. Thompson8, Victoria Dardov7, Vidya Venkatraman7, Andrea Matlock7, Jennifer E. Van Eyk7, Jacob D. Jaffe9, Malvina Papanastasiou9, Aravind Subramanian9, Todd R. Golub, Sean D. Erickson10, Mohammad Fallahi-Sichani10, Marc Hafner10, Nathanael S. Gray10, Jia-Ren Lin10, Caitlin E. Mills10, Jeremy L. Muhlich10, Mario Niepel10, Caroline E. Shamu10, Elizabeth H. Williams10, David Wrobel10, Peter K. Sorger10, Laura M. Heiser11, Joe W. Gray11, James E. Korkola11, Gordon B. Mills12, Mark A. LaBarge13, Mark A. LaBarge14, Heidi S. Feiler11, Mark A. Dane11, Elmar Bucher11, Michel Nederlof11, Damir Sudar11, Sean M. Gross11, David Kilburn11, Rebecca Smith11, Kaylyn Devlin11, Ron Margolis, Leslie Derr, Albert Lee, Ajay Pillai 
TL;DR: The LINCS program focuses on cellular physiology shared among tissues and cell types relevant to an array of diseases, including cancer, heart disease, and neurodegenerative disorders.
Abstract: The Library of Integrated Network-Based Cellular Signatures (LINCS) is an NIH Common Fund program that catalogs how human cells globally respond to chemical, genetic, and disease perturbations. Resources generated by LINCS include experimental and computational methods, visualization tools, molecular and imaging data, and signatures. By assembling an integrated picture of the range of responses of human cells exposed to many perturbations, the LINCS program aims to better understand human disease and to advance the development of new therapies. Perturbations under study include drugs, genetic perturbations, tissue micro-environments, antibodies, and disease-causing mutations. Responses to perturbations are measured by transcript profiling, mass spectrometry, cell imaging, and biochemical methods, among other assays. The LINCS program focuses on cellular physiology shared among tissues and cell types relevant to an array of diseases, including cancer, heart disease, and neurodegenerative disorders. This Perspective describes LINCS technologies, datasets, tools, and approaches to data accessibility and reusability.

300 citations

Journal ArticleDOI
TL;DR: In this article, a transcriptome and functional analysis of human induced pluripotent stem cell (iPSC)-derived brain microvascular endothelial cells (iBMECs) from HD patients or unaffected controls was performed.

179 citations

Journal ArticleDOI
TL;DR: The results therefore clarify the underlying physiological basis of this disorder, and they suggest that circumventing the diseased BBB to deliver active TH to the brain could be a viable therapeutic strategy.

164 citations

Journal ArticleDOI
TL;DR: The data suggest that mutant huntingtin impairs neurodevelopmental pathways that could disrupt synaptic homeostasis and increase vulnerability to the pathologic consequence of expanded polyglutamine repeat-associated phenotypes in neural cells and of cognitive impairment and synaptic pathology in HD model R6/2 mice.
Abstract: Neural cultures derived from Huntington’s disease (HD) patient-derived induced pluripotent stem cells were used for ‘omics’ analyses to identify mechanisms underlying neurodegeneration. RNA-seq analysis identified genes in glutamate and GABA signaling, axonal guidance and calcium influx whose expression was decreased in HD cultures. One-third of gene changes were in pathways regulating neuronal development and maturation. When mapped to stages of mouse striatal development, the profiles aligned with earlier embryonic stages of neuronal differentiation. We observed a strong correlation between HD-related histone marks, gene expression and unique peak profiles associated with dysregulated genes, suggesting a coordinated epigenetic program. Treatment with isoxazole-9, which targets key dysregulated pathways, led to amelioration of expanded polyglutamine repeat-associated phenotypes in neural cells and of cognitive impairment and synaptic pathology in HD model R6/2 mice. These data suggest that mutant huntingtin impairs neurodevelopmental pathways that could disrupt synaptic homeostasis and increase vulnerability to the pathologic consequence of expanded polyglutamine repeats over time.

162 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: In this article, the authors present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes.
Abstract: In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.

1,129 citations

Journal ArticleDOI
TL;DR: A new dedicated aspect of BioGRID annotates genome-wide CRISPR/Cas9-based screens that report gene–phenotype and gene–gene relationships, and captures chemical interaction data, including chemical–protein interactions for human drug targets drawn from the DrugBank database and manually curated bioactive compounds reported in the literature.
Abstract: The Biological General Repository for Interaction Datasets (BioGRID: https://thebiogrid.org) is an open access database dedicated to the curation and archival storage of protein, genetic and chemical interactions for all major model organism species and humans. As of September 2018 (build 3.4.164), BioGRID contains records for 1 598 688 biological interactions manually annotated from 55 809 publications for 71 species, as classified by an updated set of controlled vocabularies for experimental detection methods. BioGRID also houses records for >700 000 post-translational modification sites. BioGRID now captures chemical interaction data, including chemical-protein interactions for human drug targets drawn from the DrugBank database and manually curated bioactive compounds reported in the literature. A new dedicated aspect of BioGRID annotates genome-wide CRISPR/Cas9-based screens that report gene-phenotype and gene-gene relationships. An extension of the BioGRID resource called the Open Repository for CRISPR Screens (ORCS) database (https://orcs.thebiogrid.org) currently contains over 500 genome-wide screens carried out in human or mouse cell lines. All data in BioGRID is made freely available without restriction, is directly downloadable in standard formats and can be readily incorporated into existing applications via our web service platforms. BioGRID data are also freely distributed through partner model organism databases and meta-databases.

1,046 citations

Journal ArticleDOI
TL;DR: This review examines molecular and cellular mechanisms underlying the establishment of the blood-brain barrier, and examines how BBB dysfunction relates to neurological deficits and other pathologies in the majority of sporadic AD, PD, and ALS cases, multiple sclerosis, other neurodegenerative disorders, and acute CNS disorders.
Abstract: The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and pathogens from entering the brain. At the same time, the BBB regulates transport of molecules into and out of t...

1,033 citations

Journal ArticleDOI
TL;DR: An overview of the physiological and pathological roles of NRF2 is provided, emerging pharmacological modulators of theNRF2–KEAP1 axis are presented and associated drug development challenges are highlighted.
Abstract: The transcription factor NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (KEAP1), are critical in the maintenance of redox, metabolic and protein homeostasis, as well as the regulation of inflammation. Thus, NRF2 activation provides cytoprotection against numerous pathologies including chronic diseases of the lung and liver; autoimmune, neurodegenerative and metabolic disorders; and cancer initiation. One NRF2 activator has received clinical approval and several electrophilic modifiers of the cysteine-based sensor KEAP1 and inhibitors of its interaction with NRF2 are now in clinical development. However, challenges regarding target specificity, pharmacodynamic properties, efficacy and safety remain.

712 citations